Mass General Brigham Awards $1 Million to Biotech Breakthroughs – GlobeNewswire
Boston, MA, May 03, 2022 (GLOBE NEWSWIRE) — Ten biotech advancements from Mass General Brigham have been awarded Innovation Discovery Grants (IDG) in the 2022 round of awards for the highly competitive grant program. Each of the potential patient care and healthcare delivery breakthroughs will receive $100,000 toward ongoing development and future commercialization, based on the potential to improve health outcomes, meet articulated milestones, and attract follow-on investment as assessed…….
Boston, MA, May 03, 2022 (GLOBE NEWSWIRE) — Ten biotech advancements from Mass General Brigham have been awarded Innovation Discovery Grants (IDG) in the 2022 round of awards for the highly competitive grant program. Each of the potential patient care and healthcare delivery breakthroughs will receive $100,000 toward ongoing development and future commercialization, based on the potential to improve health outcomes, meet articulated milestones, and attract follow-on investment as assessed by independent industry experts.
“Every day, Mass General Brigham researchers are working to translate innovation into clinical applications that improve outcomes for patients faced with challenging diseases,” said Ravi Thadhani, MD, Chief Academic Officer, Mass General Brigham. “The Innovation Discovery Grants support translation of biotech research from the lab to real-world products whereby they can help more patients.”
The Mass General Brigham Harvard faculty receiving this year’s IDG awards are:
- A Novel Convection Enhanced Delivery System for Brain Malignancies, Miles Cunningham, MD, PhD, McLean Hospital
- FastLine: Single-handed Venous Access Device, Hilary Gallin, MD, Massachusetts General Hospital
- Development of KRAS Degraders in Cancer, Vidyasagar Koduri, MD, PhD, Brigham and Women’s Hospital
- Restoring Tumor Immunogenicity in Glioblastoma Multiforme (GBM), Arpita Kulkarni, PhD, Brigham and Women’s Hospital
- Developing First-in-Class mRNA Methyltransferase Inhibitor, Li Lan, MD, PhD, Massachusetts General Hospital
- Auditory Mirror Therapy for Tinnitus, Clas Linnman, PhD, Spaulding Rehabilitation Network
- Noninvasive Diagnosis of Middle-Ear Pathologies, Hamid Motallebzadeh, PhD, Massachusetts Eye and Ear
- Small-Molecule MMP Inhibitors for Allergic Inflammation, Jin Mo Park, PhD, Massachusetts General Hospital.
- Neutralizing Antibody to FSTL3 as an Immunotherapy in Ovarian Cancer, David Pepin, PhD, Massachusetts General Hospital
- Circulating Microparticle Proteins Predict Pregnancies Complicated by Placenta Accreta Spectrum, Hope Yu, MD, Brigham and Women’s Hospital
Since IDG’s inception in 2014, 65 research projects have been awarded a combined $4.2 million, and together have raised more than $199 million to further their development. This includes 14 new companies actively developing IDG-supported technologies and 19 license agreements.
“Advancements in biotech are redefining the future of medicine,” said Chris Coburn, Chief Innovation Officer, Mass General Brigham. “These grants recognize the tremendous commitment to spark innovation throughout Mass General Brigham and translate invention to the front lines of care.”
The IDG awards were announced at the World Medical Innovation Forum (WMIF) in Boston. More than 1000 healthcare leaders, industry executives, and investment experts are gathered at WMIF to explore the future of medicine in a 3-day program, this year focusing on gene and cell therapy. The Forum is presented by Mass General Brigham and Bank of America, bringing together two leading organizations with extensive healthcare expertise to advance medical breakthroughs for patients …….
